A Small Molecule Inhibitor of ETV1, YK-4-279, Prevents Prostate Cancer Growth and Metastasis in a Mouse Xenograft Model

@article{Rahim2014ASM,
  title={A Small Molecule Inhibitor of ETV1, YK-4-279, Prevents Prostate Cancer Growth and Metastasis in a Mouse Xenograft Model},
  author={Said Rahim and Tsion Zewdu Minas and Sung-hyeok Hong and Sarah Justvig and Haydar Çelik and Yasemin Saygideğer Kont and Jenny J. Han and Abraham T. Kallarakal and Yali Kong and Michelle A. Rudek and Milton L. Brown and Bhaskar Kallakury and Jeffrey A. Toretsky and Aykut {\"U}ren},
  journal={PLoS ONE},
  year={2014},
  volume={9}
}
Background The erythroblastosis virus E26 transforming sequences (ETS) family of transcription factors consists of a highly conserved group of genes that play important roles in cellular proliferation, differentiation, migration and invasion. Chromosomal translocations fusing ETS factors to promoters of androgen responsive genes have been found in prostate cancers, including the most clinically aggressive forms. ERG and ETV1 are the most commonly translocated ETS proteins. Over-expression of… 

Figures from this paper

Targeting Pan-ETS Factors Inhibits Melanoma Progression
TLDR
This is the first study identifying multiple overlapping functions of the ETS family promoting melanoma, and targeting all factors, rather than individual members, demonstrated impactful deleterious consequences in melanoma progression.
The ETS Inhibitors YK-4-279 and TK-216 Are Novel Antilymphoma Agents
TLDR
The ETS inhibitor YK-4-279 and its clinical derivative TK-216 represent a new class of agents with in vitro and in vivo antitumor activity in lymphomas, and in DLBCL they might act by targeting subtype-specific essential transcription factors.
Discovery and characterization of small molecules targeting the DNA-binding ETS domain of ERG in prostate cancer
TLDR
Results demonstrate proof-of-principal that small molecule targeting of the ERG-ETS domain can suppress transcriptional activity and reverse transformed characteristics of prostate cancers aberrantly expressing ERG.
The ETS Inhibitor YK-4-279 Suppresses Thyroid Cancer Progression Independent of TERT Promoter Mutations
TLDR
In vitro assays showed that YK-4-279 treatment sharply suppressed cell viability, colony formation, migration, and invasion, as well as induced cell cycle arrest and apoptosis in a panel of thyroid cancer cells, and this inhibitor could be a potential therapeutic agent for thyroid cancer.
The Effects and Mechanism of YK-4-279 in Combination with Docetaxel on Prostate Cancer
TLDR
The combination of docetaxel and YK-4-279 synergistically inhibited growth and induced apoptosis in human prostate cancer cells and may be an effective approach for inhibiting the growth and metastasis of prostate cancer.
EWS-FLI1 and RNA helicase A interaction inhibitor YK-4-279 inhibits growth of neuroblastoma
TLDR
YK-4-279 might be a promising agent for treatment of NB that merits further exploration, and uses the R2 public database of neuroblastoma outcome and gene expression to find that high expression of EWSR1 was associated with poor patient outcome.
Inhibition of ERG Activity in Patient-derived Prostate Cancer Xenografts by YK-4-279.
TLDR
Investigation of the effects of the ERG small-molecule inhibitor YK-4-279 on ERG+ prostate cancer patient-derived xenografts found it decreased TV, proliferation, proliferation and PSA in Severe Combined Immunodeficiency mice bearing LuCaP 23.1 tumors.
YK-4-279 effectively antagonizes EWS-FLI1 induced leukemia in a transgenic mouse model
TLDR
This in vivo study highlights the efficacy of YK-4-279 to treat EWS-FLI1 expressing neoplasms and support its therapeutic potential for patients with Ewing sarcoma and other ETS-driven malignancies.
p53 Loss Mediates Hypersensitivity to ETS Transcription Factor Inhibition Based on PARylation-Mediated Cell Death Induction
TLDR
It is uncovered that sensitivity of cancer cells against ETS factor blockade by the small molecule inhibitor YK-4-279 is strongly promoted by p53 loss in a MAPK-driven background, which suggests a novel and biomarker-driven therapeutic strategy for p53-deleted tumours, generally known for their profound therapy resistance.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 34 REFERENCES
YK-4-279 Inhibits ERG and ETV1 Mediated Prostate Cancer Cell Invasion
TLDR
YK-4-279 inhibits ERG and ETV1 biological activity in fusion-positive prostate cancer cells leading to decreased motility and invasion, which may have an impact on metastasis in prostate cancer.
Antiproliferative small-molecule inhibitors of transcription factor LSF reveal oncogene addiction to LSF in hepatocellular carcinoma
TLDR
It is concluded that LSF is the specific biological target of FQIs, and the findings support the further development of LSF inhibitors for cancer chemotherapy.
Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts
Computer-aided lead optimization derives a unique, orally bioavailable inhibitor of the signal transducer and activator of transcription (Stat)3 Src homology 2 domain. BP-1-102 binds Stat3 with an
Emergence of ETS transcription factors as diagnostic tools and therapeutic targets in prostate cancer.
  • S. Rahim, A. Uren
  • Biology, Medicine
    American journal of translational research
  • 2013
TLDR
In-vitro and in-vivo studies suggest that overexpression of ETS proteins increase cell proliferation and confer an invasive phenotype to prostate cancer cells, and Epidemiological studies demonstrate that ETS-fusion positive patients exhibit tumors corresponding to a more advanced disease.
ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss
TLDR
A new conditional mouse model is described that shows robust, homogenous ERG expression throughout the prostate, suggesting that ETS factors cause prostate-specific transformation by altering the AR cistrome, priming the prostate epithelium to respond to aberrant upstream signals such as PTEN loss.
ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients.
TLDR
The distinct biology of ETV1-associated prostate cancer suggests that this disease class may require new therapies directed to underlying programs controlled by ETV2, and the association of an ETV 1 expression signature with aggressive disease and poorer outcome in patient data is confirmed.
Inhibition of tumor metastasis by a growth factor receptor bound protein 2 Src homology 2 domain-binding antagonist.
TLDR
Results support the potential efficacy of this compound in reducing the metastatic spread of primary solid tumors and establish a critical role for Grb2 Src homology-2 domain-mediated interactions in this process.
A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing’s sarcoma
TLDR
Surface plasmon resonance screening is used to identify compounds that bind EWS-FLI1 and might block its interaction with RHA, which provides proof of principle that inhibiting the interaction of mutant cancer-specific transcription factors with the normal cellular binding partners required for their oncogenic activity provides a promising strategy for the development of uniquely effective, tumor-specific anticancer agents.
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.
...
1
2
3
4
...